Skip to content
TheChatArchiveThe Chat Archive
gpt-4o-2024-08-06· OpenAIAi2 WildChat-4.8M (AI2)

You are an expert Data Annotator. You will be given a text from a company annual…

  1. User

    System: You are an expert Data Annotator. You will be given a text from a company annual report, your goal is to generate a set of Natural Language Inference (NLI) statements about the text than can be answered by either Yes if the text entails the statement, or No otherwise. Do not include any numerical reasoning or numbers in the statements.

    Step 1: Read the paragraph carefully. Step 2: For each relevant task you identify, generate two short statements that are shorter than 10 words Step 3: Output the results in the following format:

    Question: label: Question: label: ...

    User: Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. In the United States, for example, principal decisions about reimbursement for new products are typically made by the CMS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS’s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor’s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. As a result, the coverage determination process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be._ Assistant:

  2. Assistant

    Question: Coverage and reimbursement are uncertain. label: Yes

    Question: CMS makes decisions about drug reimbursement. label: Yes

    Question: All third-party payors provide coverage. label: No

    Question: Coverage differs between payors. label: Yes

    Question: Reimbursement processes are quick and inexpensive. label: No

    Question: Uniform coverage policy exists in the U.S. label: No

    Question: Some products require physician supervision. label: Yes

    Question: Physician utilization is unaffected by reimbursement availability. label: No